Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China
1 other identifier
observational
200
1 country
1
Brief Summary
This study is a prospective, real world study.The objective is to observe the diagnosis and first-line treatment of Chinese patients with cancer of unknown primary, and collect the clinicopathological characteristics, treatment outcomes, survival and other data of the patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2021
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 18, 2021
CompletedFirst Submitted
Initial submission to the registry
June 30, 2021
CompletedFirst Posted
Study publicly available on registry
July 7, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 18, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 18, 2024
CompletedJuly 7, 2021
June 1, 2021
2 years
June 30, 2021
July 6, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Progression-free survival (PFS)
8 months
Interventions
The patient's treatment is determined by the physician in charge according to the patient's clinical situation and relevant guidelines, without additional intervention.
Eligibility Criteria
Patients with cancer of unknown primary (CUP) and are gonging to receive the first-line therapy for CUP
You may qualify if:
- Had a diagnosis of cancer of unknown primary (CUP) after a standard evaluation .
- Prepared to receive first-line therapy for CUP
You may not qualify if:
- Patients who had previously received systemic therapy for CUP
- Previous history of other cancers, except cervix cancer or basal cell carcinoma of the skin that has been cured
- The investigator considered that there were contraindications to treatment or were not appropriate to participate in this study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Fudan Universitylead
Study Sites (1)
Fudan University Shanghai Cencer Center
Shanghai, Shanghai Municipality, 200032, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
June 30, 2021
First Posted
July 7, 2021
Study Start
June 18, 2021
Primary Completion
June 18, 2023
Study Completion
June 18, 2024
Last Updated
July 7, 2021
Record last verified: 2021-06